Premium
P4‐681: OPTIMIZATION OF NOVEL M1 PAMS FOR CLINICAL DEVELOPMENT WITH ENHANCED EFFICACY WHILE AVOIDING ADVERSE EFFECT LIABILITY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Author(s) -
Rook Jerri M.,
Newhouse Paul A.,
Lindsley Craig W.,
Conn P. Jeffrey
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.09.046
Subject(s) - pharmacology , adverse effect , medicine , neuroscience , agonist , cholinergic , safety pharmacology , psychology , receptor , drug